top of page

STAAR Low-Grade Serous Ovarian Cancer
Research Program

STAAR is committed to accelerating progress in low-grade serous ovarian cancer (LGSOC) through strategic, high-impact research funding. Each year, we invite researchers from leading institutions to submit proposals that align with our annual research priorities and have the potential to meaningfully advance understanding, treatment, and outcomes for the LGSOC community.

​

All proposals are reviewed by STAAR’s Research Committee, a diverse panel of experts in medical research, clinical care, healthcare administration, and nonprofit leadership. Appointed by STAAR’s Board of Directors, the committee ensures that every grant awarded reflects our mission, upholds scientific rigor, and contributes to meaningful advancements in the field. Through this careful and transparent process, STAAR helps drive innovative science and supports researchers dedicated to improving the future for those affected by LGSOC.

2026 Funding Priorities

We are committed to funding pioneering studies that seek to understand, treat, and ultimately cure this rare and challenging disease. By fostering innovation, collaboration, and scientific excellence, we aim to accelerate the development of targeted therapies and improve the lives of patients worldwide. ​

​We believe that every breakthrough brings us closer to a future free from the burden of low-grade serous ovarian cancer.

​The STAAR Research Committee establishes funding priorities annually to help guide researchers and the committee in the  grant process.

​The committee enlists the guidance of LGSOC experts to  share the state of the research literature and then determines where gaps may exists that match with STAAR's overall mission.

  • Personalized Medicine: Support studies focused on stratifying LGSOC patients based on molecular profiles to tailor treatment approaches more effectively.

  • Immunotherapy Approaches: Invest in early-stage studies exploring the role of immunotherapy in LGSOC, including how to overcome its current limitations in this cancer subtype.

  • Novel Drug Development: Encourage research into new targeted therapies and small molecules that specifically address the unique biology of LGSOC.

  • Genetic Mutation Investigation: Further explore FDA approved treatments for cancers with shared gene mutations (i.e. KRAS, NRAS, BRAF, and Wild Type Tumors) on LGSOC.

Eligibility and Funding Details

We invite proposals from accredited research institutions, hospitals, universities, and organizations dedicated to cancer research.

Applicants must demonstrate a strong record in oncology research and a commitment to advancing low-grade serous ovarian cancer knowledge and/or treatment.

​Grantees are allowed to submit funding requests for extensions of ongoing or current research.

Funding Details:

  • Grant Amount: Up to $150,000 per project.

  • Duration: 1 to 3 years.

  • Application Deadline: Oct. 17, 2025 

  • Contact: research@staaroc.org

Have questions? Please contact research@staroc.org.
bottom of page